Changes in Management of CLL Due to COVID-19 Noted in Italy
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
COVID19
Immunotherapy May Increase Risk for Hospitalization, Severe Respiratory Illness From COVID-19
Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.
Active Anticancer Treatment Associated With Poor COVID-19 Prognosis
Patients with cancer are more susceptible to infection with SARS-CoV-2, and patients receiving active anticancer treatment have a poorer prognosis.
First Guidelines for Providing Oncology Pharmacy Services in COVID-19
The first set of guidelines for providing oncology pharmacy services to cancer patients during the COVID-19 pandemic was recently published.
When COVID-19 Meets CLL: Limited Evidence Offers Some Hope for Good Outcomes
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
Prior PD-1 Blockade Did Not Appear to Influence the Severity of COVID-19 in Patients With Lung Cancer
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
COVID-19 Outcomes With Anticancer Drugs
This fact sheet discusses associations between anticancer therapies and outcomes of COVID-19 among patients with cancer.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Prior Chemotherapy Associated With Increased Risk of Death in Patients With Thoracic Cancer and COVID-19
Results of TERAVOLT showed that chemotherapy alone or in combination was significantly associated with increased risk of death for those with thoracic cancer and COVID-19.
Treatment With Hydroxychloroquine-Azithromycin, Progressive Cancer Found to Increase Risk of Death for Patients With COVID-19
Only 2 patients received hydroxychloroquine as part of a clinical trial, and about 10% were taking the drug at the time of their COVID-19 presentation.
-
Loading...
-
Loading...
Next post in ASCO 2020
